JP Morgan Chase’s Guardant Health GH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $26.2M | Buy |
304,317
+33,278
| +12% | +$3.34M | ﹤0.01% | 1856 |
|
|
2025
Q4 | $27.7M | Sell |
271,039
-222,782
| -45% | -$19.9M | ﹤0.01% | 1796 |
|
|
2025
Q3 | $30.9M | Buy |
493,821
+300,519
| +155% | +$16.3M | ﹤0.01% | 1752 |
|
|
2025
Q2 | $10.1M | Buy |
193,302
+17,079
| +10% | +$763K | ﹤0.01% | 2545 |
|
|
2025
Q1 | $7.51M | Sell |
176,223
-500,903
| -74% | -$21.6M | ﹤0.01% | 2799 |
|
|
2024
Q4 | $20.7M | Buy |
677,126
+477,582
| +239% | +$13.4M | ﹤0.01% | 2015 |
|
|
2024
Q3 | $4.58M | Sell |
199,544
-229,841
| -54% | -$6.51M | ﹤0.01% | 3282 |
|
|
2024
Q2 | $12.4M | Buy |
429,385
+269,134
| +168% | +$6.27M | ﹤0.01% | 2269 |
|
|
2024
Q1 | $3.31M | Sell |
160,251
-322,562
| -67% | -$6.91M | ﹤0.01% | 3443 |
|
|
2023
Q4 | $13.1M | Buy |
482,813
+59,090
| +14% | +$1.55M | ﹤0.01% | 2204 |
|
|
2023
Q3 | $12.6M | Sell |
423,723
-264,227
| -38% | -$9.29M | ﹤0.01% | 2055 |
|
|
2023
Q2 | $24.6M | Buy |
687,950
+44,853
| +7% | +$1.29M | ﹤0.01% | 1548 |
|
|
2023
Q1 | $15.1M | Buy |
643,097
+458,041
| +248% | +$13.1M | ﹤0.01% | 1903 |
|
|
2022
Q4 | $5.03M | Sell |
185,056
-812,649
| -81% | -$37.2M | ﹤0.01% | 2808 |
|
|
2022
Q3 | $53.7M | Buy |
997,705
+822,954
| +471% | +$42.2M | 0.01% | 1020 |
|
|
2022
Q2 | $7.05M | Sell |
174,751
-15,313
| -8% | -$759K | ﹤0.01% | 2466 |
|
|
2022
Q1 | $12.6M | Sell |
190,064
-51,601
| -21% | -$3.53M | ﹤0.01% | 2149 |
|
|
2021
Q4 | $24.2M | Buy |
241,665
+125,082
| +107% | +$12.9M | ﹤0.01% | 1663 |
|
|
2021
Q3 | $14.6M | Sell |
116,583
-266,455
| -70% | -$31.7M | ﹤0.01% | 2032 |
|
|
2021
Q2 | $47.6M | Buy |
383,038
+12,715
| +3% | +$1.71M | 0.01% | 1246 |
|
|
2021
Q1 | $56.5M | Sell |
370,323
-209,814
| -36% | -$31.7M | 0.01% | 1109 |
|
|
2020
Q4 | $74.8M | Buy |
580,137
+355,395
| +158% | +$40.9M | 0.01% | 895 |
|
|
2020
Q3 | $25M | Sell |
224,742
-114,580
| -34% | -$10.5M | ﹤0.01% | 1344 |
|
|
2020
Q2 | $27.5M | Buy |
339,322
+60,297
| +22% | +$4.86M | 0.01% | 1176 |
|
|
2020
Q1 | $19.4M | Sell |
279,025
-29,008
| -9% | -$2.23M | ﹤0.01% | 1279 |
|
|
2019
Q4 | $24.1M | Sell |
308,033
-1,661,164
| -84% | -$120M | ﹤0.01% | 1436 |
|
|
2019
Q3 | $126M | Buy |
1,969,197
+1,885,792
| +2,261% | +$166M | 0.03% | 587 |
|
|
2019
Q2 | $7.02M | Buy |
83,405
+32,293
| +63% | +$2.47M | ﹤0.01% | 2373 |
|
|
2019
Q1 | $3.92M | Buy |
51,112
+4,430
| +9% | +$246K | ﹤0.01% | 2793 |
|
|
2018
Q4 | $1.75M | Buy |
+46,682
| New | +$1.72M | ﹤0.01% | 3372 |
|
Other funds holding GH
VPM
VCM
JP Morgan Chase's GH Position: Q1 2026 in Review
JP Morgan Chase increased its Guardant Health (GH) stake by 12% in Q1 2026, buying an estimated $3.34M and bringing the position to 304,317 shares worth $26.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1856.
JP Morgan Chase first reported a position in GH in Q4 2018 and has held it in 30 quarters since. The position peaked at $126M in Q3 2019. 481 funds tracked by Wall St. Rank hold GH as of Q1 2026.
- JP Morgan Chase held 304,317 shares of Guardant Health worth $26.2M as of Q1 2026.
- JP Morgan Chase bought 33,278 Guardant Health shares in Q1 2026, an estimated $3.34M.
- Guardant Health made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #1856 holding.
- JP Morgan Chase first reported a position in Guardant Health in Q4 2018 and has held it in 30 quarters since.
- JP Morgan Chase's Guardant Health position peaked at $126M in Q3 2019.
- 481 funds tracked by Wall St. Rank held Guardant Health as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.